Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Innovation / R&D category. Vertex Pharmaceuticals Inc. faces ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $4.38 per share for the third quarter of 2024, ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its target price raised by research analysts at Scotiabank from ...

US biopharma Vertex Pharmaceuticals was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’s ...

Nov 4 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF ...

The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...